

Resource Summary Report

Generated by [dkNET](#) on Sep 9, 2026

Anti-CD4 antibody [EPR19514]

RRID:AB_2686917

Type: Antibody

Proper Citation

Abcam Cat# ab183685, RRID:AB_2686917

Antibody Information

URL: http://antibodyregistry.org/AB_2686917

Proper Citation: Abcam Cat# ab183685, RRID:AB_2686917

Target Antigen: CD4

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IHC-P, IHC-Fr, WB in MDS.
Info: Used by Czech Centre for Phenogenomics

Antibody Name: Anti-CD4 antibody [EPR19514]

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: EPR19514

Antibody ID: AB_2686917

Vendor: Abcam

Catalog Number: ab183685

Record Creation Time: 20231110T034046+0000

Record Last Update: 20260830T011332+0000

Ratings and Alerts

- Used by Czech Centre for Phenogenomics - Czech Centre for Phenogenomics
<https://www.phenogenomics.cz/>

No alerts have been found for Anti-CD4 antibody [EPR19514] .

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 112 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Adan-Villaescusa E, et al. (2026) Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma. Cell reports. Medicine, 7(4), 102717.

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer immunology research, 14(1), 90.

Song X, et al. (2026) MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors. Med (New York, N.Y.), 7(1), 100936.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Wang X, et al. (2026) Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. Cancer cell, 44(3), 658.

Laforêts F, et al. (2026) Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer. iScience, 29(3), 114858.

Foidart P, et al. (2026) Whole-genome doubling drives immune evasion by silencing antigen presentation. Cancer cell, 44(7), 1418.

Liao F, et al. (2026) Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression. Cancer research, 86(8), 1968.

Lei F, et al. (2026) Therapeutic Effect of Gemcitabine Combined With Angelica Polysaccharide on Triple Negative Breast Cancer in Mice. Integrative cancer therapies, 25, 15347354251414897.

Gu H, et al. (2026) FAP⁺ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(18), e06239.

Ho YH, et al. (2026) Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer. *Cell*, 189(14), 4276.

Luo Y, et al. (2026) CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. *Clinical science (London, England : 1979)*, 140(1).

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. *bioRxiv : the preprint server for biology*.

Mateus-Tique J, et al. (2026) Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth. *Cancer cell*, 44(3), 534.

Thomas OG, et al. (2026) Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis. *Cell*.

Nakanishi N, et al. (2026) VEGF-C-mediated cardiac lymphangiogenesis promotes inflammation resolution in autoimmune acute myocarditis in mice. *Cardiovascular research*, 122(6), 707.

Wang L, et al. (2026) The circadian gene *Dec2* promotes pancreatic cancer progression and dormancy through immune evasion. *Developmental cell*, 61(6), 1208.

Yang N, et al. (2026) Pan-cancer macrophage atlas uncovers that MHC-II^{high} TAMs induce Treg activation through physical interactions. *Cell reports*, 45(4), 117230.

Yang S, et al. (2026) Oat- β -glucan potentiates anti-PD-1 efficacy through *Faecalibacterium prausnitzii*-derived butyrate and indole-3-propionic acid. *Cell host & microbe*, 34(7), 1333.

Vitiello PP, et al. (2025) Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. *Cancer cell*, 43(7), 1296.